Global Mesenchymal Stem Cell Therapy Market
The Mesenchymal Stem Cell (MSC) Therapy market refers to the industry focused on the research, development, and commercialization of treatments based on mesenchymal stem cells. These stem cells, which can differentiate into a variety of cell types, are used in regenerative medicine and are sourced from bone marrow, adipose tissue, umbilical cord blood, and other tissues. Here’s an overview of the MSC therapy market:
Market Overview
Market Size and Growth:
The MSC therapy market has seen significant growth due to advancements in stem cell research and increasing demand for regenerative medicine.
It is projected to continue growing as more clinical trials demonstrate the efficacy and safety of MSC-based therapies.
Applications:
Orthopedics: Treatment of bone and cartilage diseases, such as osteoarthritis and bone fractures.
Cardiology: Therapy for myocardial infarction and other heart conditions.
Neurology: Treatment of neurodegenerative diseases like Parkinson's and Alzheimer's, as well as stroke recovery.
Autoimmune Diseases: Therapy for conditions like Crohn's disease, multiple sclerosis, and lupus.
Wound Healing: Enhancing the healing process of chronic wounds and burns.
Others: Potential applications in treating liver diseases, diabetes, and pulmonary conditions.
Sources of MSCs:
Bone Marrow: Traditional and most common source, though extraction is invasive.
Adipose Tissue: Rich in MSCs and easier to extract through liposuction.
Umbilical Cord Blood: Non-invasive collection and high proliferative capacity.
Placental Tissue: Contains a high concentration of MSCs and is obtained without harm to the donor.
Regional Analysis
North America:
Market Characteristics: Leading market due to advanced healthcare infrastructure, significant investment in research and development, and favorable regulatory environment.
Key Players: Companies like Mesoblast Ltd, Athersys Inc., and Osiris Therapeutics (now part of Smith & Nephew).
Trends: Increasing number of clinical trials, growing adoption of MSC therapies in clinical practice, and high healthcare expenditure.
Europe:
Market Characteristics: Strong market driven by supportive regulatory frameworks and significant research activities.
Key Players: TiGenix (acquired by Takeda), ReNeuron Group plc, and Anterogen Co., Ltd.
Trends: Growing focus on personalized medicine, substantial funding for stem cell research, and collaborations between academic institutions and biopharma companies.
Asia-Pacific:
Market Characteristics: Fast-growing market with increasing investments in healthcare infrastructure and biotechnology.
Key Players: Medipost Co., Ltd, Beike Biotechnology, and Cynata Therapeutics.
Trends: Expansion of clinical trials, rising medical tourism, and supportive government initiatives.
Latin America:
Market Characteristics: Emerging market with growing interest in regenerative medicine and stem cell therapy.
Key Players: Celltex Therapeutics, Bioheart Inc. (now U.S. Stem Cell), and Cryo-Cell International.
Trends: Increasing awareness of stem cell therapies, developing healthcare infrastructure, and regulatory improvements.
Middle East and Africa:
Market Characteristics: Nascent market with increasing adoption of advanced medical treatments.
Key Players: Limited presence of major players, but growing interest from companies like Abu Dhabi Stem Cells Center.
Trends: Gradual increase in clinical trials and investments in healthcare infrastructure.
Market Drivers
Technological Advancements: Innovations in stem cell isolation, culture, and differentiation techniques.
Increasing Prevalence of Chronic Diseases: Growing need for effective treatments for conditions like osteoarthritis, cardiovascular diseases, and neurodegenerative disorders.
Rising Geriatric Population: Higher incidence of age-related diseases that can be treated with MSC therapies.
Growing Investments: Increased funding from both public and private sectors for stem cell research and development.
Regulatory Support: Progressive regulatory frameworks supporting the approval and commercialization of stem cell therapies.
Challenges
High Costs: Expensive research and development, as well as high costs of therapies.
Regulatory Hurdles: Navigating complex regulatory requirements across different regions.
Ethical Concerns: Ethical issues related to stem cell sourcing and use.
Scalability: Challenges in scaling up production to meet clinical and commercial demands.
Future Trends
Personalized Medicine: Increasing focus on developing personalized MSC therapies tailored to individual patient needs.
Combination Therapies: Growing interest in combining MSC therapies with other treatments for enhanced efficacy.
AI and Data Analytics: Use of artificial intelligence and big data to optimize MSC therapy development and clinical outcomes.
Global Collaborations: Rising number of partnerships between companies, research institutions, and healthcare providers to advance MSC therapies.
The Mesenchymal Stem Cell Therapy market is a rapidly evolving sector with significant potential to transform the landscape of regenerative medicine and address unmet medical needs across various therapeutic areas.
| Report AttributesA2:B10+A2:B12A2:B10A2:B9B8A2:B11A2:B8 | Details |
| Study Period | 2023 to 2033 |
| Base Year | 2023 |
| FORECAST PERIOD | 2024-2030 |
| HISTORICAL PERIOD | 2020-2023 |
| UNIT | Value (USD Billion) |
| KEY COMPANIES PROFILED | • Mesoblast Limited • TiGenix • Osiris Therapeutics • Celgene Corporation • Vericel Corporation • Athersys Inc. • NuVasive Inc. • Orthofix Medical Inc. • Regeneus Ltd. • Pluristem Therapeutics Inc. • ReNeuron Group plc • Anterogen Co. Ltd. • Pharmicell Co. Ltd. • Cytori Therapeutics Inc. • Mesoblast Limited • Stempeutics Research Pvt. Ltd. • Mesenchymal Stem Cells of Georgia LLC • Capricor Therapeutics • Celltex Therapeutics Corporation • Cells for Cells S.A. • Others |
| SEGMENTS COVERED | By Type, By Application, and By Geography |
| CUSTOMIZATION SCOPE | Free report customization (equivalent to up to 4 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Mesenchymal Stem Cell Therapy Market Segments
By Type
· Autologous
· Allogeneic
By Source of Isolation
· Bone Marrow
· Cord Blood
· Peripheral Blood
· Fallopian Tube
· Fetal Liver
· Lung
· Adipose Tissues
By Application
· Disease Modelling
· Drug Development & Discovery
· Stem Cell Banking
· Tissue Engineering
· Toxicology Studies
· Others
Mesenchymal Stem Cell Therapy Market Players
· Mesoblast Limited
· TiGenix
· Osiris Therapeutics
· Celgene Corporation
· Vericel Corporation
· Athersys Inc.
· NuVasive Inc.
· Orthofix Medical Inc.
· Regeneus Ltd.
· Pluristem Therapeutics Inc.
· ReNeuron Group plc
· Anterogen Co. Ltd.
· Pharmicell Co. Ltd.
· Cytori Therapeutics Inc.
· Mesoblast Limited
· Stempeutics Research Pvt. Ltd.
· Mesenchymal Stem Cells of Georgia LLC
· Capricor Therapeutics
· Celltex Therapeutics Corporation
· Cells for Cells S.A.
· Others
Table of Contents
Chapter 1. Preface
1.1 Report Description and Scope
1.2 Research scope
1.3 Research methodology
1.3.1 Market Research Type
1.3.2 Market Research Methodology
Chapter 2. Executive Summary
2.1 Global Mesenchymal Stem Cell Therapy Market, (2024 – 2033) (USD Billion)
2.2 Global Mesenchymal Stem Cell Therapy Market: snapshot
Chapter 3. Global Mesenchymal Stem Cell Therapy Market – Industry Analysis
3.1 Mesenchymal Stem Cell Therapy Market: Market Dynamics
3.2 Market Drivers
3.2.1 Increase in prevalence of chronic diseases
3.2.2 Growing prominence of regenerative medicine
3.3 Market Restraints
3.4 Market Opportunities
3.5 Market Challenges
3.6 Porter’s Five Forces Analysis
3.7 Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis By Type
3.7.2 Market Attractiveness Analysis By Source of Isolation
3.7.3 Market Attractiveness Analysis By Application
Chapter 4. Global Mesenchymal Stem Cell Therapy Market- Competitive Landscape
4.1 Company market share analysis
4.1.1 Global Mesenchymal Stem Cell Therapy Market: company market share, 2023
4.2 Strategic development
4.2.1 Acquisitions & mergers
4.2.2 New Product launches
4.2.3 Agreements, partnerships, cullaborations, and joint ventures
4.2.4 Research and development and Regional expansion
4.3 Price trend analysis
Chapter 5. Global Mesenchymal Stem Cell Therapy Market – Type Analysis
5.1 Global Mesenchymal Stem Cell Therapy Market Overview: By Type
5.1.1 Global Mesenchymal Stem Cell Therapy Market Share, By Type, 2023 and 2033
5.2 Autologous
5.2.1 Global Mesenchymal Stem Cell Therapy Market by Autologous, 2024 – 2033 (USD Billion)
5.3 Allogeneic
5.3.1 Global Mesenchymal Stem Cell Therapy Market by Allogeneic, 2024 – 2033 (USD Billion)
Chapter 6. Global Mesenchymal Stem Cell Therapy Market – Source of Isolation Analysis
6.1 Global Mesenchymal Stem Cell Therapy Market Overview: By Source of Isolation
6.1.1 Global Mesenchymal Stem Cell Therapy Market Share, By Source of Isolation, 2023 and 2033
6.2 Bone Marrow
6.2.1 Global Mesenchymal Stem Cell Therapy Market by Bone Marrow, 2024 – 2033 (USD Billion)
6.3 Cord Blood
6.3.1 Global Mesenchymal Stem Cell Therapy Market by Cord Blood, 2024 – 2033 (USD Billion)
6.4 Peripheral Blood
6.4.1 Global Mesenchymal Stem Cell Therapy Market by Peripheral Blood, 2024 – 2033 (USD Billion)
6.5 Fallopian Tube
6.5.1 Global Mesenchymal Stem Cell Therapy Market by Fallopian Tube, 2024 – 2033 (USD Billion)
6.6 Fetal Liver
6.6.1 Global Mesenchymal Stem Cell Therapy Market by Fetal Liver, 2024 – 2033 (USD Billion)
6.7 Lung
6.7.1 Global Mesenchymal Stem Cell Therapy Market by Lung, 2024 – 2033 (USD Billion)
6.8 Adipose Tissues
6.8.1 Global Mesenchymal Stem Cell Therapy Market by Adipose Tissues, 2024 – 2033 (USD Billion)
Chapter 7. Global Mesenchymal Stem Cell Therapy Market – Application Analysis
7.1 Global Mesenchymal Stem Cell Therapy Market Overview: By Application
7.1.1 Global Mesenchymal Stem Cell Therapy Market Share, By Application, 2023 and 2033
7.2 Disease Modelling
7.2.1 Global Mesenchymal Stem Cell Therapy Market by Disease Modelling, 2024 – 2033 (USD Billion)
7.3 Drug Development & Discovery
7.3.1 Global Mesenchymal Stem Cell Therapy Market by Drug Development & Discovery, 2024 – 2033 (USD Billion)
7.4 Stem Cell Banking
7.4.1 Global Mesenchymal Stem Cell Therapy Market by Stem Cell Banking, 2024 – 2033 (USD Billion)
7.5 Tissue Engineering
7.5.1 Global Mesenchymal Stem Cell Therapy Market by Tissue Engineering, 2024 – 2033 (USD Billion)
7.6 Toxicology Studies
7.6.1 Global Mesenchymal Stem Cell Therapy Market by Toxicology Studies, 2024 – 2033 (USD Billion)
7.7 Others
7.7.1 Global Mesenchymal Stem Cell Therapy Market by Others, 2024 – 2033 (USD Billion)
Chapter 8. Mesenchymal Stem Cell Therapy Market – Regional Analysis
8.1 Global Mesenchymal Stem Cell Therapy Market Regional Overview
8.2 Global Mesenchymal Stem Cell Therapy Market Share, by Region, 2023 & 2033 (USD Billion)
8.3. North America
8.3.1 North America Mesenchymal Stem Cell Therapy Market, 2024 – 2033 (USD Billion)
8.3.1.1 North America Mesenchymal Stem Cell Therapy Market, by Country, 2024 – 2033 (USD Billion)
8.4 North America Mesenchymal Stem Cell Therapy Market, by Type, 2024 – 2033
8.4.1 North America Mesenchymal Stem Cell Therapy Market, by Type, 2024 – 2033 (USD Billion)
8.5 North America Mesenchymal Stem Cell Therapy Market, by Source of Isolation, 2024 – 2033
8.5.1 North America Mesenchymal Stem Cell Therapy Market, by Source of Isolation, 2024 – 2033 (USD Billion)
8.6 North America Mesenchymal Stem Cell Therapy Market, by Application, 2024 – 2033
8.6.1 North America Mesenchymal Stem Cell Therapy Market, by Application, 2024 – 2033 (USD Billion)
8.7. Europe
8.7.1 Europe Mesenchymal Stem Cell Therapy Market, 2024 – 2033 (USD Billion)
8.7.1.1 Europe Mesenchymal Stem Cell Therapy Market, by Country, 2024 – 2033 (USD Billion)
8.8 Europe Mesenchymal Stem Cell Therapy Market, by Type, 2024 – 2033
8.8.1 Europe Mesenchymal Stem Cell Therapy Market, by Type, 2024 – 2033 (USD Billion)
8.9 Europe Mesenchymal Stem Cell Therapy Market, by Source of Isolation, 2024 – 2033
8.9.1 Europe Mesenchymal Stem Cell Therapy Market, by Source of Isolation, 2024 – 2033 (USD Billion)
8.10 Europe Mesenchymal Stem Cell Therapy Market, by Application, 2024 – 2033
8.10.1 Europe Mesenchymal Stem Cell Therapy Market, by Application, 2024 – 2033 (USD Billion)
8.11. Asia Pacific
8.11.1 Asia Pacific Mesenchymal Stem Cell Therapy Market, 2024 – 2033 (USD Billion)
8.11.1.1 Asia Pacific Mesenchymal Stem Cell Therapy Market, by Country, 2024 – 2033 (USD Billion)
8.12 Asia Pacific Mesenchymal Stem Cell Therapy Market, by Type, 2024 – 2033
8.12.1 Asia Pacific Mesenchymal Stem Cell Therapy Market, by Type, 2024 – 2033 (USD Billion)
8.13 Asia Pacific Mesenchymal Stem Cell Therapy Market, by Source of Isolation, 2024 – 2033
8.13.1 Asia Pacific Mesenchymal Stem Cell Therapy Market, by Source of Isolation, 2024 – 2033 (USD Billion)
8.14 Asia Pacific Mesenchymal Stem Cell Therapy Market, by Application, 2024 – 2033
8.14.1 Asia Pacific Mesenchymal Stem Cell Therapy Market, by Application, 2024 – 2033 (USD Billion)
8.15. Latin America
8.15.1 Latin America Mesenchymal Stem Cell Therapy Market, 2024 – 2033 (USD Billion)
8.15.1.1 Latin America Mesenchymal Stem Cell Therapy Market, by Country, 2024 – 2033 (USD Billion)
8.16 Latin America Mesenchymal Stem Cell Therapy Market, by Type, 2024 – 2033
8.16.1 Latin America Mesenchymal Stem Cell Therapy Market, by Type, 2024 – 2033 (USD Billion)
8.17 Latin America Mesenchymal Stem Cell Therapy Market, by Source of Isolation, 2024 – 2033
8.17.1 Latin America Mesenchymal Stem Cell Therapy Market, by Source of Isolation, 2024 – 2033 (USD Billion)
8.18 Latin America Mesenchymal Stem Cell Therapy Market, by Application, 2024 – 2033
8.18.1 Latin America Mesenchymal Stem Cell Therapy Market, by Application, 2024 – 2033 (USD Billion)
8.19. The Middle-East and Africa
8.19.1 The Middle-East and Africa Mesenchymal Stem Cell Therapy Market, 2024 – 2033 (USD Billion)
8.19.1.1 The Middle-East and Africa Mesenchymal Stem Cell Therapy Market, by Country, 2024 – 2033 (USD Billion)
8.20 The Middle-East and Africa Mesenchymal Stem Cell Therapy Market, by Type, 2024 – 2033
8.20.1 The Middle-East and Africa Mesenchymal Stem Cell Therapy Market, by Type, 2024 – 2033 (USD Billion)
8.21 The Middle-East and Africa Mesenchymal Stem Cell Therapy Market, by Source of Isolation, 2024 – 2033
8.21.1 The Middle-East and Africa Mesenchymal Stem Cell Therapy Market, by Source of Isolation, 2024 – 2033 (USD Billion)
8.22 The Middle-East and Africa Mesenchymal Stem Cell Therapy Market, by Application, 2024 – 2033
8.22.1 The Middle-East and Africa Mesenchymal Stem Cell Therapy Market, by Application, 2024 – 2033 (USD Billion)
Chapter 9. Company Profiles
9.1 Mesoblast Limited
9.1.1 Overview
9.1.2 Financials
9.1.3 Product Portfolio
9.1.4 Business Strategy
9.1.5 Recent Developments
9.2 TiGenix
9.2.1 Overview
9.2.2 Financials
9.2.3 Product Portfolio
9.2.4 Business Strategy
9.2.5 Recent Developments
9.3 Osiris Therapeutics
9.3.1 Overview
9.3.2 Financials
9.3.3 Product Portfolio
9.3.4 Business Strategy
9.3.5 Recent Developments
9.4 Celgene Corporation
9.4.1 Overview
9.4.2 Financials
9.4.3 Product Portfolio
9.4.4 Business Strategy
9.4.5 Recent Developments
9.5 Vericel Corporation
9.5.1 Overview
9.5.2 Financials
9.5.3 Product Portfolio
9.5.4 Business Strategy
9.5.5 Recent Developments
9.6 Athersys Inc.
9.6.1 Overview
9.6.2 Financials
9.6.3 Product Portfolio
9.6.4 Business Strategy
9.6.5 Recent Developments
9.7 NuVasive Inc.
9.7.1 Overview
9.7.2 Financials
9.7.3 Product Portfolio
9.7.4 Business Strategy
9.7.5 Recent Developments
9.8 Orthofix Medical Inc.
9.8.1 Overview
9.8.2 Financials
9.8.3 Product Portfolio
9.8.4 Business Strategy
9.8.5 Recent Developments
9.9 Regeneus Ltd.
9.9.1 Overview
9.9.2 Financials
9.9.3 Product Portfolio
9.9.4 Business Strategy
9.9.5 Recent Developments
9.10 Pluristem Therapeutics Inc.
9.10.1 Overview
9.10.2 Financials
9.10.3 Product Portfolio
9.10.4 Business Strategy
9.10.5 Recent Developments
9.11 ReNeuron Group plc
9.11.1 Overview
9.11.2 Financials
9.11.3 Product Portfolio
9.11.4 Business Strategy
9.11.5 Recent Developments
9.12 Anterogen Co. Ltd.
9.12.1 Overview
9.12.2 Financials
9.12.3 Product Portfolio
9.12.4 Business Strategy
9.12.5 Recent Developments
9.13 Pharmicell Co. Ltd.
9.13.1 Overview
9.13.2 Financials
9.13.3 Product Portfolio
9.13.4 Business Strategy
9.13.5 Recent Developments
9.14 Cytori Therapeutics Inc.
9.14.1 Overview
9.14.2 Financials
9.14.3 Product Portfolio
9.14.4 Business Strategy
9.14.5 Recent Developments
9.15 Mesoblast Limited
9.15.1 Overview
9.15.2 Financials
9.15.3 Product Portfolio
9.15.4 Business Strategy
9.15.5 Recent Developments
9.16 Stempeutics Research Pvt. Ltd.
9.16.1 Overview
9.16.2 Financials
9.16.3 Product Portfolio
9.16.4 Business Strategy
9.16.5 Recent Developments
9.17 Mesenchymal Stem Cells of Georgia LLC
9.17.1 Overview
9.17.2 Financials
9.17.3 Product Portfolio
9.17.4 Business Strategy
9.17.5 Recent Developments
9.18 Capricor Therapeutics
9.18.1 Overview
9.18.2 Financials
9.18.3 Product Portfolio
9.18.4 Business Strategy
9.18.5 Recent Developments
9.19 Celltex Therapeutics Corporation
9.19.1 Overview
9.19.2 Financials
9.19.3 Product Portfolio
9.19.4 Business Strategy
9.19.5 Recent Developments
9.20 Cells for Cells S.A.
9.20.1 Overview
9.20.2 Financials
9.20.3 Product Portfolio
9.20.4 Business Strategy
9.20.5 Recent Developments
9.21 Others.
9.21.1 Overview
9.21.2 Financials
9.21.3 Product Portfolio
9.21.4 Business Strategy
9.21.5 Recent Developments
Mesenchymal Stem Cell Therapy Market Segments
By Type
· Autologous
· Allogeneic
By Source of Isolation
· Bone Marrow
· Cord Blood
· Peripheral Blood
· Fallopian Tube
· Fetal Liver
· Lung
· Adipose Tissues
By Application
· Disease Modelling
· Drug Development & Discovery
· Stem Cell Banking
· Tissue Engineering
· Toxicology Studies
· Others
Mesenchymal Stem Cell Therapy Market Players
· Mesoblast Limited
· TiGenix
· Osiris Therapeutics
· Celgene Corporation
· Vericel Corporation
· Athersys Inc.
· NuVasive Inc.
· Orthofix Medical Inc.
· Regeneus Ltd.
· Pluristem Therapeutics Inc.
· ReNeuron Group plc
· Anterogen Co. Ltd.
· Pharmicell Co. Ltd.
· Cytori Therapeutics Inc.
· Mesoblast Limited
· Stempeutics Research Pvt. Ltd.
· Mesenchymal Stem Cells of Georgia LLC
· Capricor Therapeutics
· Celltex Therapeutics Corporation
· Cells for Cells S.A.
Others
